ABSTRACT

Urosepsis is a type of sepsis caused by infection of urogenital tract and characterized with an inflammatory response. Ability of Pseudomonas aeruginosa to develop a resistance to various antibiotics presents as a therapeutic challenge for the physician. In the present case report, we discuss a case of 70-year-old male patient suffering from urosepsis due to multi-drug resistant (MDR) P. aeruginosa pathogen. This patient was treated with a novel antibiotic adjuvant entity Elores™ (ceftriaxone / sulbactam / disodium edetate). The present case shows Elores™ to be safe and efficacious in the treatment of urosepsis due to MDR P. aeruginosa. Elores™ can be considered as drug of choice in the treatment of MDR P. aeruginosa infections.

Keywords: Elores™, Pseudomonas aeruginosa, Antibiotic resistance, Urosepsis, Complicated urinary tract infection, Disodium edetate.

INTRODUCTION

Urosepsis is defined as sepsis caused by infection of urogenital tract and characterized with an inflammatory response. Urosepsis accounts for 25% of total sepsis cases [1]. About 40% cases of nosocomial infections are of urinary tract infections (UTIs) [2]. Obstruction of urine is a frequent reason for sepsis. Complicated UTI (cUTI) is the common cause of urosepsis [2]. Gram-negative bacteria are commonly responsible for urosepsis. Among these Gram-negative bacteria, Escherichia coli is responsible for 50% of cases while Proteus spp., Enterobacter and Klebsiella spp. Collectively comprises 30% of cases. Pseudomonas aeruginosa causes 5% of total urosepsis cases infected with Gram-negative bacteria [2]. The ability of P. aeruginosa to develop the resistance to various antibiotics poses a therapeutic challenge for the physician [3,4].

In the present case report, we discuss a case of 70-years-old male suffering from urosepsis due to multi-drug resistant (MDR) P. aeruginosa which was successfully treated with Elores™.

CASE REPORT

A 70-year-old male patient was admitted to hospital with complaints of pain, weakness, burning micturition, and renal calculi. He was operated 52 days before, for renal calculi with bilateral percutaneous nephrolithotomy under spinal anesthesia. He presented with operated 52 days before, for renal calculi with bilateral percutaneous nephrolithotomy under spinal anesthesia. He presented with systemic symptoms such as fever, chills, rigors, and vomiting for the last 3 days. He was presumptively diagnosed with urosepsis, chronic kidney disease, and obstructive uropathy.

The treatment was started empirically with intravenous piperacillin/tazobactam 4.5 g every 12 hrs. Hemogram showed total leucocyte count (TLC) to be 16,500/cumm. Urine sample was sent for culture and susceptibility test. Based on diagnostic criteria for sepsis, clinical and laboratory examinations patient was diagnosed with urosepsis. Urine culture and sensitivity report showed the presence of pathogen P. aeruginosa, which was resistant to most of antibiotics as listed in Table 1. As P. aeruginosa was resistant to piperacillin/tazobactam so piperacillin/tazobactam was discontinued. Elores™ 3 g every 12 hrs was administered by intravenously for an infusion time of 90 minutes for 7 days. TLC normalized after 7 days (8500/cumm).

DISCUSSION

P. aeruginosa causes various hospital acquired infections characterized by substantial morbidity and mortality. P. aeruginosa pathogen presents a serious challenge for the treatment of urosepsis because of its ability to develop resistance to antibiotics. Thus, selection of antibiotic should be done very judiciously [5]. In the present case study, culture and sensitivity report revealed the resistance of P. aeruginosa to piperacillin/tazobactam, so this antibiotic was discontinued. P. aeruginosa was susceptible to colistin in culture and susceptibility test. However, colistin was not used because of nephrotoxicity and neurotoxicity concerns [6,7]. cUTI and urosepsis are not approved indications for tigecycline [8]. Elores™ is safe and efficacious in Pseudomonas infection. Moreover, this antibiotic combination is eliminated (Ceftriaxone: 50-60%; Sulbactam: 70-80%) mainly in urine [9]. Elores™ had 4-5 fold lower minimum inhibitor concentration as compared to ceftriaxone and sulbactam [10].

Elores™ is highly potent and efficacious in the treatment of metallo-β-lactamases (MBL) producing P. aeruginosa [5]. A study published in 2013 showed susceptibility of 515 isolated (extended-spectrum-β-lactamases [ESBL]: 45.63%, MBL: 16.89%, ESBL + MBL: 14.36%) of P. aeruginosa to antibiotics. Isolates with MBL and ESBL + MBL genes were resistant to meropenem, imipenem, ceftazidime, cefepime, and ELORES™.

Table 1: Culture and susceptibility profile of urine sample

<table>
<thead>
<tr>
<th>Antibiotic</th>
<th>P. aeruginosa</th>
</tr>
</thead>
<tbody>
<tr>
<td>Carbapenem</td>
<td>Resistant</td>
</tr>
<tr>
<td>Gentamicin</td>
<td>Resistant</td>
</tr>
<tr>
<td>Piperacillin/tazobactam</td>
<td>Resistant</td>
</tr>
<tr>
<td>Cefopenzone + sulbactam</td>
<td>Resistant</td>
</tr>
<tr>
<td>Cefepime</td>
<td>Resistant</td>
</tr>
<tr>
<td>Cefotaxime</td>
<td>Resistant</td>
</tr>
<tr>
<td>Ceftazidime</td>
<td>Resistant</td>
</tr>
<tr>
<td>Ceftriaxime</td>
<td>Resistant</td>
</tr>
<tr>
<td>Ciprofloxacin</td>
<td>Resistant</td>
</tr>
<tr>
<td>Levofloxacin</td>
<td>Resistant</td>
</tr>
<tr>
<td>Norfloxacin</td>
<td>Resistant</td>
</tr>
<tr>
<td>Ofloxacin</td>
<td>Resistant</td>
</tr>
<tr>
<td>Aztreonam</td>
<td>Resistant</td>
</tr>
<tr>
<td>Nitrofurantoin</td>
<td>Resistant</td>
</tr>
<tr>
<td>Amikacin</td>
<td>Intermediate</td>
</tr>
<tr>
<td>Tobramycin</td>
<td>Intermediate</td>
</tr>
<tr>
<td>Elores™</td>
<td>Sensitive</td>
</tr>
</tbody>
</table>

P. aeruginosa: Pseudomonas aeruginosa
piperacilline + tazobactum antibiotics and susceptibility to Elores™ was 97.3% and 95.1% and for doripenem was 11.3% and 19.5% for MBL and ESBL + MBL, respectively [5].

All the three components of Elores™ have synergistic effect against microbial infection. Ceftriaxone acts as antibiotic while sulbactam is irreversible β lactamase inhibitor. Disodium edetate chelates zinc ions (required for MBL activity), enhances the membrane permeation, and inhibits efflux pump [9,10]. A Phase III clinical trials results showed 83.33% cure rate in UTIs [4]. That's why in this case after discontinuation of piperacillin/tazobactam, Elores™ was given. In the present case, we observed therapeutic efficacy of Elores™ in P. aeruginosa infection. Clinical cure justifies the use of Elores™ as an antibiotic therapy.

CONCLUSION

The present case shows Elores™ to be safe and efficacious in the treatment of urosepsis due to MDR P. aeruginosa. Elores™ can be considered as drug of choice in the treatment of MDR P. aeruginosa infections.

REFERENCES

9. Elores™ Monograph, Venus medicine research center, Baddi, India. [Last accessed on 2016 Feb 27].